Eli Lilly completes $3.2 billion acquisition of Morphic to enhance IBD treatments

Pallavi Madhiraju- August 18, 2024

Eli Lilly and Company has finalised its acquisition of Morphic Holding, Inc. in a landmark $3.2 billion deal, aimed at enhancing treatment options for inflammatory ... Read More

Eli Lilly’s mirikizumab triumphs in Phase 3 Crohn’s disease study

Pallavi Madhiraju- October 14, 2023

Eli Lilly and Company (NYSE: LLY), a pharmaceutical leader, unveiled that mirikizumab, its cutting-edge interleukin-23p19 antagonist, has demonstrated its prowess against placebo in the critical ... Read More

Eli Lilly completes $2.4bn acquisition of DICE Therapeutics

Pallavi Madhiraju- August 10, 2023

Eli Lilly and Company (Lilly) has finalized its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE) for $2.4 billion, bolstering its immunology portfolio with the inclusion ... Read More

Aeglea BioTherapeutics buys Spyre Therapeutics to revolutionize IBD treatment

Pallavi Madhiraju- June 25, 2023

Aeglea BioTherapeutics, a Nasdaq-listed company, has acquired Spyre Therapeutics, a private biotech company dedicated to advancing a promising pipeline of antibody therapeutics aimed at revolutionizing ... Read More

Lilly to acquire biopharma company DICE Therapeutics in $2.4bn deal

Pallavi Madhiraju- June 20, 2023

Eli Lilly and Company (Lilly) has agreed to acquire US-based biopharmaceutical company DICE Therapeutics, listed on the Nasdaq, in an all-cash deal worth $2.4 billion. ... Read More

Roivant Sciences, Pfizer create new business for inflammatory disease drug

Raghuram Kadari- December 3, 2022

Roivant Sciences, a US healthcare company, and Pfizer have established a new Vant to develop and commercialize PF-06480605 (now RVT-3101) for inflammatory and fibrotic bowel ... Read More

Seres Therapeutics begins phase 1b trial of SER-301 in ulcerative colitis

pharmanewsdaily- November 8, 2020

Seres Therapeutics has dosed the first patient in a phase 1b clinical trial, which is assessing SER-301 for the treatment of active mild-to-moderate ulcerative colitis ... Read More

BMS’ Zeposia succeeds in True North clinical trial in ulcerative colitis

pharmanewsdaily- October 11, 2020

Bristol Myers Squibb (BMS) said that the phase 3 True North clinical trial evaluating Zeposia (ozanimod) in adult patients with moderate to severe ulcerative colitis ... Read More

Gilead Sciences, Second Genome form IBD drug discovery alliance

pharmanewsdaily- April 9, 2020

Gilead Sciences has entered into a four-year deal worth up to $338 million with California-based clinical-stage company Second Genome to discover targets and drug candidates ... Read More

Protagonist Therapeutics secures $22m to advance IBD treatment

pharmanewsdaily- August 6, 2018

Protagonist Therapeutics, a clinical-stage biopharmaceutical company specializing in the discovery and development of novel peptide-based drugs, has successfully raised $22 million in new equity financing. ... Read More